Clinical Trial: Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2)

U.S., Sept. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07811908) titled 'Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2)' on Sept. 04.

Brief Summary: This was Cohort C2 of the Platform study (NCT05750628) to evaluate the efficacy and safety of Cipargamin + KLU156 in participants with uncomplicated Plasmodium falciparum malaria.

Study Start Date: Feb. 12

Study Type: INTERVENTIONAL

Condition: Uncomplicated Plasmodium Falciparum Malaria

Intervention: DRUG: KAE609

oral capsules administered in combination with KLU156

DRUG: SoC (Coartem)

Standard of Care

DRUG: KLU156

oral sachet formulation (KAF...